Cell and gene therapy manufacturing sales will grow through 2036, led by gene therapy manufacturing at 63.9% of the therapy type segment in 2026. The market was valued at USD 32.12 billion in 2025 and is expected to be worth USD 336.25 billion by 2036, creating an incremental opportunity of USD 296.49 billion.